HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

P Brice Selected Research

LNH87-2 protocol

8/2000Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


P Brice Research Topics

Disease

9Hodgkin Disease (Hodgkin's Disease)
01/2021 - 04/2000
7Lymphoma (Lymphomas)
04/2021 - 08/2000
7Neoplasms (Cancer)
01/2019 - 08/2000
4Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
11/2020 - 03/2014
4Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
01/2019 - 12/2000
3Mycosis Fungoides
01/2020 - 03/2014
3B-Cell Lymphoma (Lymphoma, B Cell)
03/2014 - 10/2002
3Non-Hodgkin Lymphoma (Lymphosarcoma)
10/2009 - 08/2000
2Infections
02/2015 - 10/2012
1Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
04/2021
1Disease Progression
01/2019
1Hematologic Neoplasms (Hematological Malignancy)
01/2019
1Exfoliative Dermatitis (Erythroderma)
01/2019
1Parapsoriasis
01/2019
1Hematologic Diseases (Blood Diseases)
01/2019
1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
02/2015
1Residual Neoplasm
10/2012
1Lymphoproliferative Disorders (Lymphoproliferative Disorder)
01/2009
1Sclerosis
08/2001
1Neutropenia
01/2001
1Leukemia
08/2000
1Fibrosis (Cirrhosis)
05/2000
1Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
02/2000

Drug/Important Bio-Agent (IBA)

4Rituximab (Mabthera)FDA Link
01/2019 - 10/2002
3Etoposide (VP 16)FDA LinkGeneric
11/2020 - 08/2000
3IfosfamideFDA LinkGeneric
11/2020 - 08/2000
3Brentuximab VedotinIBA
01/2020 - 01/2019
3Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2019 - 08/2000
2Monoclonal AntibodiesIBA
01/2019 - 10/2002
2Doxorubicin (Adriamycin)FDA LinkGeneric
01/2019 - 11/2008
2Prednisone (Sone)FDA LinkGeneric
01/2019 - 11/2008
2Vincristine (Oncovin)FDA LinkGeneric
01/2019 - 11/2008
2N- (2- (4- bromocinnamylamino)ethyl)- 5- isoquinolinesulfonamide (h89)IBA
08/2001 - 04/2000
1Methotrexate (Mexate)FDA LinkGeneric
04/2021
1Bendamustine HydrochlorideFDA Link
12/2019
1monomethyl auristatin EIBA
01/2019
1ofatumumabFDA Link
02/2015
1Alemtuzumab (Campath)FDA Link
03/2014
1Vinblastine (Vinblastine Sulfate)FDA Link
11/2008
1Procarbazine (Matulane)FDA Link
11/2008
1Dacarbazine (DIC)FDA LinkGeneric
11/2008
1Bleomycin (Blenoxane)FDA LinkGeneric
11/2008
1Antineoplastic Agents (Antineoplastics)IBA
10/2002
1Surface Antigens (Surface Antigen)IBA
10/2002
1Granulocyte Colony-Stimulating Factor (G-CSF)IBA
01/2001
1Asparaginase (Elspar)FDA Link
08/2000
1Carmustine (FIVB)FDA Link
08/2000
1Cytarabine (Cytosar-U)FDA LinkGeneric
08/2000
1Topoisomerase II InhibitorsIBA
08/2000
1GalliumIBA
05/2000

Therapy/Procedure

10Stem Cell Transplantation
01/2020 - 02/2000
10Drug Therapy (Chemotherapy)
01/2019 - 04/2000
7Therapeutics
01/2021 - 08/2000
3Radiotherapy
04/2019 - 04/2000
3Immunotherapy
04/2019 - 02/2007
2Salvage Therapy
03/2014 - 01/2003
2Hematopoietic Stem Cell Transplantation
10/2012 - 01/2009
2Aftercare (After-Treatment)
10/2002 - 07/2001
1Combination Drug Therapy (Combination Chemotherapy)
01/2019
1Tissue Transplantation
01/2019
1Bone Marrow Transplantation (Transplantation, Bone Marrow)
07/2016
1Time-to-Treatment
08/2014
1Transplantation
01/2001
1LNH87-2 protocol
08/2000